NVLX Inks Marketing Plan For Gentler Tattos–Stock Soars 37%
May 27, 2009 @ 11:46 am
Say hello to an old friend, Nuvilex, Inc. (NVLX), a micro-cap stock we’ve been covering since 2007. Heading into trading today, shares of the emerging healthcare consumer products company sold for a ho-hum $.038.
In over two years, I’ve watched the stock start at $.18, hit a high of $.45, and sink to a recent low of $.03. By mid-day, shares rose 13% and finished up 37% higher ($.13) on some promising news.
Formerly EFoodSafety.com, Inc., Nuvlex reported today that one of its products, Infinitink (the world’s first permanent tattoo ink designed for easier removal) will be marketed, promoted, distributed and sold by Jayhur Enterprises in tatto-heavy Australia and New Zealand for the next five years.
So now we’ve got something to talk about. Nuvilex estimates that if Jayhur Enterprises
captures 30% of today’s market by the end of the agreement, the annual revenue could be as high as $3.75 million.
Get this…15% of Australia’s population over 15 years of age is considering a tattoo. Apparently, though, the permanent aspect of having “Mom” carved into an arm isn’t that appealing. These ‘fence sitters’ are excellent candidates for artists offering Infinitink tattoos. That group represents 25% of the over 18-year-old U.S. populatiJayhur Enterprises joins with MT.Derm, GmbH, Berlin, Germany as
Infinitink international distributors. MT.Derm owns Infinitink European distribution rights and since 2006 has been a development partner with Freedom2. Nuvilex is seeking a distributor for Latin and South America.
Infinitink was selected as one of Time Magazine’s ‘Products of the Year’ in its November 12, 2007 issue. Since then, Infinitink has undergone further testing and development and now some serious marketing efforts.
I don’t know how much higher the stock will go from here, but this could be the kickstart it needed to take off.
2 Comments
RSS feed for comments on this post.
Leave a comment
Line and paragraph breaks automatic, e-mail address never displayed, HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>
There’s more from NVLX.
The following is from an interview with NVLX’s CEO conducted by The Wall Street Transcript, 1 June 2009:
TWST: What are your priorities for Nuvilex? What will make the next 12 to 24 months successful for the company?
Mr. Schmieg: In a single word, performance. We need to instill a new level of confidence in our investors through performance - setting and achieving our goals. Our initial performance milestone will be in topside revenue growth, which we have given guidance of between $3 million and $5 million for the current fiscal year that runs from May 1, 2009 through April 30, 2010. In the near term, we will be launching our Last Shot Hangover Remedy, a safe and novel blend of essential minerals and nutrients developed to help the body metabolize the sugar in alcohol, thereby preventing or minimizing a hangover. The preventative hangover remedy is packaged in a two-ounce tube and it is meant to be taken in one shot, followed by 16 ounces of water, before going to sleep. Following a successful spring break initiative to market Last Shot along with our InfinitInk, we have seen positive reactions among the key 18 to 25 year-old demographic group. We believe that the product has the potential to make significant revenue contributions.
TWST: Would you give us some insight into your technology platform as well as the lead products that you have under development?
Mr. Schmieg: There are various technology platforms. They include a technology we call P2E, which is an encapsulation technology for developing safe tattoo inks and can also be used for drug delivery. The second is Cinnergen. Cinnergen is our supplement formula that is engineered to help pre-diabetics and diabetics manage their metabolism. Cinnergen has now become a family of products that includes Cinnergen itself; Cinnechol, a supplement to support good cardiovascular health, and two new products. The first is our Last Shot Hangover Remedy, which is a product taken at the end of a night of imbibing and it will eliminate or nearly eliminate all of your hangover symptoms the next morning. The other is Prevorex, an appetite aid to help those who are either on diets or trying to control their calorie intake. Our third technology is Citroxin, which starts as an eco-friendly cleaner that is highly effective as a germicide and antiviral surface cleaner. Citroxin is also being developed as a nematicide and a homeopathic medicine.
The Wall Street Transcript is a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs and research analysts. This 107 page special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online .
Sorry- Dropping this one to make room for my China move.
Comment by Irvt — 6/1/2009 @ 9:48 am
Glad to see a blog on ole EfoodSafety now Nuvilex.
Hope this means you are covering again?
Editor’s response: Only of they continue to do something worth talking about. We’ll see.
Comment by Ron — 5/27/2009 @ 12:45 pm